The in-person requirement creates a new barrier for women seeking medication abortion
In a country still reckoning with the boundaries of bodily autonomy and federal authority, a federal appeals court in New Orleans has temporarily reimposed a requirement that the abortion pill mifepristone be obtained in person rather than through the mail — reversing a pandemic-era FDA policy that had quietly expanded reproductive access across state lines. The ruling, born from a Louisiana lawsuit rooted in that state's declaration of personhood at conception, does not ban the drug outright, but it narrows the road to it for millions of women in states where abortion is already restricted. It is the latest chapter in a longer American argument about who holds the power to define life, medicine, and the limits of the state.
- A federal appeals court has abruptly overridden a lower court pause and reinstated in-person dispensing requirements for mifepristone, the most widely used abortion method in the United States.
- For women in states with abortion bans, the ruling closes a critical door — the ability to receive medication abortion by mail or telemedicine — leaving travel or forgoing care as the remaining options.
- The decision deepens a legal fracture already exposed by the Supreme Court's 2022 reversal of Roe v. Wade, even as that same Court unanimously rejected a similar mifepristone restriction just one year ago.
- Abortion rights advocates warn the ruling defies established medical science and broad public opposition, while anti-abortion leaders celebrate it as a decisive blow against what they call reckless federal overreach.
- The order holds while litigation continues, meaning its impact is immediate — uneven across state lines, but acutely felt wherever reproductive healthcare is already scarce.
On Friday, the Fifth Circuit Court of Appeals in New Orleans issued an order temporarily requiring that mifepristone — the first drug in the most common two-pill abortion regimen — be dispensed only in person, reversing a 2023 FDA rule that had allowed it to be prescribed via telemedicine and delivered by mail.
The ruling arose from a lawsuit filed by Louisiana, a state where abortion is effectively banned, whose law declares personhood to begin at conception. The court found that the FDA's mail-order policy directly undermined that declaration. The order will remain in place as the case moves through the courts.
Mifepristone was first approved by the FDA in 2000 and for two decades required in-person dispensing. That changed during the pandemic, when the in-person requirement was suspended, and in 2023 the FDA made the change permanent — a shift that significantly expanded access, especially in states with abortion restrictions. The Fifth Circuit's ruling now reverses that expansion.
The decision overrides a lower court that had paused the case pending a Trump administration review of FDA regulations. It arrives in the shadow of the Supreme Court's 2024 unanimous rejection of a similar mifepristone challenge — though that ruling left room for new legal avenues.
Responses split sharply along familiar lines. Louisiana's Attorney General and national anti-abortion groups called the ruling a victory for life. Civil liberties attorneys and state officials in states like New York countered that it defies science and settled law, and assured residents that access within their borders would not change.
The practical consequences are immediate and unequal. In states where abortion remains legal, women retain access through existing medical channels. In states with bans or severe restrictions, the in-person requirement now stands as a new barrier — one that may force travel, or leave medication abortion out of reach entirely.
On Friday, a federal appeals court in New Orleans issued an order that will reshape how Americans can access one of the most common methods of ending a pregnancy. The Fifth Circuit Court of Appeals temporarily reinstated a requirement that the abortion pill mifepristone be dispensed only in person—reversing a 2023 decision by the Food and Drug Administration that had allowed the drug to be sent by mail or obtained through telemedicine.
The ruling stems from a lawsuit brought by Louisiana, a state where abortion is effectively banned. In its decision, the court wrote that the FDA's mail-order policy violated Louisiana's own law declaring that "every unborn child is a human being from the moment of conception and is, therefore, a legal person." The court framed the FDA's action as directly undermining state law. The order will remain in effect as the case continues through the courts.
Mifepristone is the first drug in a two-pill regimen used to end a pregnancy. It works by blocking progesterone, the hormone necessary for pregnancy to continue. The second drug, misoprostol, empties the uterus. Together, the two medications are about 95 percent effective, and medical follow-up is required less than one percent of the time, according to US studies. The American College of Obstetrics and Gynecologists and other mainstream medical organizations have affirmed that both drugs are safe.
The FDA first approved mifepristone in 2000 for pregnancies up to seven weeks, then extended that window to ten weeks in 2016. For two decades, the drug could only be dispensed in person. But in April 2021, as the pandemic disrupted normal medical practice, the FDA suspended the in-person requirement. Two years later, in 2023, the agency made that change permanent, allowing doctors to prescribe the pill without seeing patients face-to-face. The shift dramatically expanded access, particularly for women in states where abortion is restricted or banned.
The Fifth Circuit's decision overrides a lower court ruling from earlier this month that had paused the case while the Trump administration conducts its own review of the FDA's regulations. The timing matters: in 2024, the US Supreme Court unanimously rejected an earlier attempt to restrict mifepristone access. But that decision, which came two years after the court eliminated the nationwide constitutional right to abortion, left room for other legal challenges to proceed.
Louisiana's Attorney General, Liz Murrill, celebrated the ruling, claiming the FDA's mail-order policy "facilitated the deaths of thousands of Louisiana babies." She said she looked forward to continuing to defend what she called "women and babies" as the case moves forward. Marjorie Dannenfelser, president of Susan B Anthony Pro-Life America, called the decision "a huge victory" against what she termed Biden's "reckless mail-order abortion drug regime."
But advocates for abortion access pushed back sharply. Julia Kaye, an attorney with the American Civil Liberties Union, said the ruling "defies clear science and settled law" and advances an agenda that most Americans oppose. New York's Attorney General, Letitia James, issued a statement assuring residents that abortion access would remain legal in her state, including medication abortion, regardless of the appellate court's decision.
The practical effect of the ruling is immediate and uneven. In states where abortion remains legal—like New York, California, and others—women can still access mifepristone through established medical channels. But in states with abortion bans or severe restrictions, the in-person requirement creates a new barrier. Women seeking medication abortion in those states now face the choice of traveling to a state where the procedure is legal, or forgoing the option entirely. The ruling does not ban mifepristone outright, but it narrows the pathway to obtaining it in much of the country.
Notable Quotes
This decision defies clear science and settled law and advances an anti-abortion agenda that is deeply unpopular with the American people.— Julia Kaye, American Civil Liberties Union
In New York, our laws ensure that anyone who needs abortion care can seek it here. That has not changed, and we will continue to protect access to abortion, including medication abortion.— Letitia James, New York Attorney General
The Hearth Conversation Another angle on the story
Why does the in-person requirement matter so much? Isn't mifepristone still available?
It's available, but only if you can get to a clinic in person. That's a real barrier for people in rural areas, or those without time off work, or money for travel. Mail-order meant someone in Texas or Louisiana could get the pills at home. Now they can't.
But the Supreme Court already rejected restrictions on this drug in 2024. Why is this court decision happening now?
The Supreme Court rejected one specific challenge, but it didn't settle the broader question. It left the door open for other lawsuits. This is Louisiana taking a different legal angle—arguing that the FDA's rule violates Louisiana's own state law.
So this is about states versus the federal government?
Partly. But it's also about what counts as a legal person. Louisiana's law says life begins at conception. The court agreed that the FDA's mail-order policy undermines that state policy. It's a collision between federal drug regulation and state abortion law.
How effective is mifepristone, really?
About 95 percent effective. Medical follow-up is needed less than one percent of the time. The major medical organizations all say it's safe. That's not in dispute—even the court didn't argue the drug is unsafe.
So what happens next?
The case continues through the courts. This ruling stays in effect while that happens. Women in states with abortion bans lose mail-order access immediately. Women in states where abortion is legal aren't affected. But the legal fight isn't over.